| Name | Title | Contact Details |
|---|
Erlandsen and Associates Inc is a East Wenatchee, WA-based company in the Business Services sector.
Mote Marine Lab is a Sarasota, FL-based company in the Business Services sector.
Wilmar Group, Llc is a Lake Forest, IL-based company in the Business Services sector.
Jet Metal Corp (TSX.V: JET) (OTCQB: JETMF) ("Jet Metal") is a uranium and vanadium explorer and developer with projects across North America. Its CMB Uranium/Vanadium Project, located in Newfoundland and Labrador, Canada, encompasses the Two Time Zone, which as an Indicated uranium resource estimate of 2.33 M lbs (1.82 M tonnes @0.058% U3O8) and an Inferred uranium resource estimate of 3.373 M lbs (3.16 M tonnes @0.053% U3O8). Additional information about the CMB Uranium-Vandium Project can be found in the technical report filed on SEDAR at www.sedar.com entitled: “Technical Report on the CMBNW Property, Newfoundland and Labrador, Canada: prepared for Jet Metal (formerly Crosshair Exploration and Mining) and Silver Spruce Resources dated June 22, 2009. In addition to the CMB Project, Jet Metal's Bootheel Project is located in uranium mining friendly Wyoming and has the potential to be mined using in-situ recovery methods. Wyoming has the largest known uranium ore reserves in the United States and currently leads the U.S. in uranium production. Stewart Wallis, P.Geo., is a Director of the Company and a Qualified Person as defined by National Instrument 43-101 for the above mentioned projects. The QP is a member in good standing of the Association of Professional Engineers and Geoscientists of British Columbia (APEGBC) as a registered Professional Geoscientist (P.Geo.).
Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.